NASDAQ:IMNM Immunome Q3 2025 Earnings Results & Report $17.58 -1.57 (-8.20%) Closing price 04:00 PM EasternExtended Trading$17.60 +0.02 (+0.11%) As of 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Immunome missed analyst earnings expectations in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.65 versus the -$0.57 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 6, 2025TimeBefore Market OpensConference Call4:00 PM ET Immunome EPS ResultsActual EPS-$0.65Consensus EPS -$0.57Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersImmunome Revenue ResultsActual RevenueN/AExpected Revenue$0.73 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsImmunome's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Immunome Q3 2025 Earnings FAQ Did Immunome beat earnings estimates for Q3 2025? Immunome (NASDAQ:IMNM) reported earnings of -$0.65 per share for Q3 2025, missing the consensus estimate of -$0.57. The report was announced on Thursday, November 6, 2025. When is Immunome's next earnings date? Immunome's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunome on the company's earnings history page. Immunome Earnings HeadlinesCritical Analysis: Arbutus Biopharma (NASDAQ:ABUS) and Immunome (NASDAQ:IMNM)October 10 at 4:29 AM | americanbankingnews.comImmunome (IMNM) Gets a Hold from Stifel NicolausOctober 7, 2026 | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 13 at 1:00 AM | Stansberry Research (Ad)Immunome, Inc. (NASDAQ:IMNM) Stock Has Average Target Price of $34.25October 7, 2026 | americanbankingnews.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 6, 2026 | businesswire.comImmunome Restructures BMS Deal, Gains Key Patent RightsOctober 5, 2026 | tipranks.comSee More Immunome Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email. Email Address About ImmunomeImmunome (NASDAQ:IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer and immune-related diseases. The company uses its antibody discovery and development capabilities to identify potentially differentiated treatments designed to address significant unmet medical needs. Immunome’s research activities are centered on building a pipeline of monoclonal antibody programs, including candidates directed at targets relevant to oncology and inflammatory or immune-mediated conditions. Its work encompasses target discovery, antibody engineering, preclinical development and clinical-stage drug development. The company was founded in 2008 and is headquartered in Exton, Pennsylvania. Immunome initially developed its technology around the discovery of antibodies from human immune cells and applied that expertise to infectious-disease research, including programs related to COVID-19. Clay B. Siegall, Ph.D., serves as president and chief executive officer.View Immunome ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
